R&G PharmaStudies Co., Ltd. have recently merged with Suzhou HQ Bioscience Co., Ltd. Suzhou HQ Bioscience is now a subsidiary of R&G. Dr. Dafang ZHONG signed the Merger Agreement with R&G on behalf of Suzhou HQ Bioscience.
Dr. ZHONG is a reputable, leading scientific expert and CDE Reviewer. In his earlier years he traveled to Germany to study for his PhD in Pharmaceutical Chemistry at the University of Bonn before completing his postdoctoral research at the Central Laboratory of German Pharmacists. After his return to China in 1994 he successively held positions of Doctoral Supervisor and Drug Metabolism and Pharmacokinetics Laboratory Director in Shenyang Pharmaceutical University. In 1996 he was awarded the National Science Fund for Distinguished Young Scholars. In 2005 he became a researcher in the Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Director of the Center for Drug Metabolism Research.
Dr. Zhong has led a number of research subjects sponsored by the National Science Fund and National 863 Program, as well as an R&D public service platform called the Shanghai Drug Metabolism Institution which is affiliated to Shanghai Municipal Science & Technology Commission. In 2015 he presided over the drafting of the “guiding principles for quantitative analysis of biological samples” and the “guiding principles of human bioavailability and biological equivalence tests in pharmaceutical preparations” for the Chinese Pharmacopoeia, 2015 edition. Dr. ZHONG is the founder and Board Chairman of Suzhou HQ Bioscience Co., Ltd.
In 2016, Suzhou HQ Bioscience successfully passed the Ministry of Health’s Pharmacokinetics Quality Assessment. Their main services include drug absorption, distribution, metabolism, excretion and toxicokinetics studies; Drug Product Analysis and Metabolic Product Analysis of biological samples; Drug Metabolism screening of candidate compounds; Bioavailability of pharmaceutical formulations and Biological Equivalence assessments; Preparation of chemical compounds for Drug Metabolism and the development of new methods, etc.
With this merger R&G’s service scope has now extended from clinical development to preclinical development. In order to provide our clients with a more comprehensive service package, R&G shall continue to increase its reach as a CRO, in a conscious effort to contribute even more to the development of drugs in China and abroad.